CTR20260366 Human immunoglobulin(Hualan Biological Engineering) Purpura, Thrombocytopenic, Idiopathic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines CTR20260366 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 24 August 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why CTR20260366 is a hot trial to watch
Purpura, Thrombocytopenic, Idiopathic is being segmented by mechanism, treatment setting, geography and endpoint architecture. CTR20260366 is notable because it evaluates Human immunoglobulin(Hualan Biological Engineering) in a Phase 3 design sponsored by Hualan Biological Engineering Chongqing Co., Ltd.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | CTR20260366 |
| Official title | 评价静注人免疫球蛋白（10%）治疗原发免疫性血小板减少症（ITP）的有效性和安全性的开放、单臂、多中心Ⅲ期临床试验 |
| Phase / status | Phase 3 / 进行中 （尚未招募） |
| Intervention | Human immunoglobulin(Hualan Biological Engineering) |
| Sponsor | Hualan Biological Engineering Chongqing Co., Ltd. |
| Geography | China |
| Enrollment | [object Object] |
| Primary endpoint | |
| Endpoint time frame | 7天内 |
| Primary completion / readout proxy | Not reported |
Protocol design and endpoint interpretation
The indexed record describes a Phase 3 study of Human immunoglobulin(Hualan Biological Engineering) in Purpura, Thrombocytopenic, Idiopathic.
Allocation is 非随机化, masking is 开放, and the intervention model is 单臂试验. Planned enrollment of [object Object] participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Primary endpoint (7天内) — 提升血小板的有效率：首次用药治疗后7天内，血小板计数≥30×109/L并且提高到基线2倍以上的受试者比例。
- Primary endpoint (90天内) — 从签署知情同意书开始，按试验流程在规定的时点或时间范围开始观察并收集、记录每个受试者的安全性数据。
Readout outlook and evidence gap
The current protocol points to Not reported as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: Human immunoglobulin(Hualan Biological Engineering) is indexed as No normalized modality returned, with target No normalized target returned, mechanism No normalized mechanism returned, and global highest development status No normalized global status returned.
Company & Deal Intelligence MCP profile: Hualan Biological Engineering Chongqing Co., Ltd. is resolved to a normalized organization record in Chongqing Shi, China. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
CTR20260366 provides a focused lens on Purpura, Thrombocytopenic, Idiopathic development. Its value will be determined by whether Human immunoglobulin(Hualan Biological Engineering) can convert the current Phase 3 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
